BACKGROUND: Asthma is a heterogeneous chronic airway disease, which may be classified into different phenotypes. YKL-40 is a chitin-binding glycoprotein with unclear functions, but its expression is associated with inflammation and tissue remodeling. However, few studies have explored whether YKL-40 is associated with inflammatory phenotypes of asthma. METHODS: The study had two parts. Study I (nâ=â115) was a one-year prospective cohort designed to explore the relationship of serum YKL-40 levels with inflammatory phenotypes of asthma at baseline, and during exacerbations. Study II (nâ=â62) was a four-week prospective cohort designed to define whether serum YKL-40 levels could predict responses to a fixed anti-asthma regimen. YKL-40, IL-6 and CCL22 levels were detected using ELISA, and a sputum inflammatory panel (including IL-1β, IL-5, IL-8 and TNF-α) was assessed using Luminex-based MILLIPLEX assay. RESULTS: Study I: Serum YKL-40 levels in non-eosinophilic asthma (NEA) i.e. neutrophilic (47.77 [29.59, 74.97] ng/mL, nâ=â40) and paucigranulocytic (47.36 [28.81, 61.68] ng/mL, nâ=â31) were significantly elevated compared with eosinophilic asthma (31.05 [22.41, 51.10] ng/mL, nâ=â44) (Pâ=â0.015). Serum YKL-40levels positively correlated with blood neutrophils, sputum IL-1β and plasma IL-6 but negatively correlated with serum IgE and blood eosinophils (all Pââ¤â0.05). Baseline YKL-40 levels predicted moderate to severe exacerbations within a one-year period (aORâ=â4.13, 95% CIâ=â[1.08, 15.83]). Study II: Serum YKL-40 was an independent biomarker of negative responses to anti-asthma regimens (adjusted Odds Ratio [aOR]â=â0.82, 95% CIâ=â[0.71, 0.96]. CONCLUSIONS: These studies show that YKL-40 is a non-type 2 inflammatory signature for NEA, which could predict responsiveness or insensitivity to anti-asthma medications and more exacerbations. Further studies are needed to assess whether monitoring YKL-40 levels could provide potential implications for clinical relevance.
Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations.
几丁质酶样蛋白 YKL-40 与炎症表型、抗哮喘反应和未来病情加重相关
阅读:5
作者:Liu Lei, Zhang Xin, Liu Ying, Zhang Li, Zheng Jing, Wang Ji, Hansbro Philip M, Wang Lei, Wang Gang, Hsu Alan Chen-Yu
| 期刊: | Respiratory Research | 影响因子: | 5.000 |
| 时间: | 2019 | 起止号: | 2019 May 22; 20(1):95 |
| doi: | 10.1186/s12931-019-1051-9 | 研究方向: | 免疫/内分泌 |
| 疾病类型: | 哮喘 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
